Late HIV presentation: epidemiology, clinical implications and management

References

• Poznansky MC, Coker R, Skinner C et al. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. Br. Med. J.311, 156–158 (1995).
   PubMed Web of Science ®Google Scholar
• Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir. Ther.12(6), 841–841 (2007).
   PubMed Web of Science ®Google Scholar
• Girardi E, Sabin CA, d’Arminio Monforte A. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J. Acquir. Immune Defic. Syndr.46(Suppl. 1), S3–S8 (2007).
   PubMed Web of Science ®Google Scholar
• Fisher M. Late diagnosis of HIV infection: major consequences and missed opportunities. Curr. Opin. Infect. Dis.21, 1–3 (2008).
   PubMed Web of Science ®Google Scholar
• Wong K-H, Lu S, Lee SS, Low K, Wan WY. Temporal trends and factors associated with late HIV diagnosis in Hong Kong, a low HIV prevalence locality. AIDS Patient Care STDs17, 461–469 (2003).
   PubMed Web of Science ®Google Scholar
• Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS24(13), 2109–2115 (2010).
   PubMed Web of Science ®Google Scholar
• Fleishman JA, Yehia BR, Moore RD, Gebo KA; for the HIV Research Network. The economic burden of late entry into medical care for patients with HIV infection. Med. Care48(12), 1071–1079 (2010).
   PubMed Web of Science ®Google Scholar
• Torrone EA, Thomas JC, Leone PA, Hightow-Weidman LB. Late diagnosis of HIV in young men in North Carolina. Sex. Trans. Dis.34(11), 846–848 (2007).
   PubMed Web of Science ®Google Scholar
• Delpierre C, Lauwers-Cances V, Pugliese P et al. Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur. J. Pub. Health18(3), 345–347 (2007).
   PubMedGoogle Scholar
• Borghi V, Girardi E, Bellelli S et al. Late presenters in an HIV surveillance system in Italy during the period 1992–2006. J. Acquir. Immun. Defic. Syndr.49(3), 282–286 (2008).
   PubMed Web of Science ®Google Scholar
• Bonjour MA, Montaqne M, Zambrano M et al. Determinants of late disease-stage presentation at diagnosis of HIV infection in Venezuela: a case–case comparison. AIDS Res. Ther.5, 6 (2008).
   PubMedGoogle Scholar
• Thanawuth N, Chongsuvivatwong V. Late HIV diagnosis and delay in CD4 count measurement among HIV-infected patients in Southern Thailand. AIDS Care20(1), 43–50 (2008).
   PubMed Web of Science ®Google Scholar
• Mugavero MJ, Castellano C, Edelman D, Hicks C. Late diagnosis of HIV infection: the role of age and sex. Am. J. Med.120, 370–373 (2007).
   PubMed Web of Science ®Google Scholar
• Sampaio M, Sampaio J, Haguihara T, Ventin FO, Brites C. Clinical and laboratory profile of HIV-positive patients at the moment of diagnosis in Bahia, Brazil. Braz. J. Infect. Dis.11(4), 395–398 (2007).
   PubMedGoogle Scholar
• Mussini C, Manzardo C, Johnson M et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS22(18), 2461–2469 (2008).
   PubMed Web of Science ®Google Scholar
• Jean-Jacques M, Walensky RP, Aaronson WH, Chang Y, Freedberg KA. Late diagnosis of HIV infection at two academic medical centers: 1994–2004. AIDS Care20, 977–983 (2008).
   PubMed Web of Science ®Google Scholar
• Carrizosa CM, Blumberg EJ, Hovell MF et al. Determinants and prevalence of late HIV testing in Tijuana, Mexico. AIDS Patient Care STDs24(5), 333–340 (2010).
   PubMed Web of Science ®Google Scholar
• Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S. Late diagnosis of HIV infection. Trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J. Acquir. Immun. Defic. Syndr.43(4), 491–494 (2006).
   PubMed Web of Science ®Google Scholar
• Begovac J, Gedike K, Lukas D, Lepej SZ. Late presentation to care for HIV infection in Croatia and the effect of interventions during the Croatian Global Fund Project. AIDS Behav.12, S48–S53 (2008).
   Google Scholar
• Sullivan AK, Curtis H, Sabin CA, Johnson MA. Newly diagnosed HIV infections: review in UK and Ireland. BMJ330, 1301–1302 (2005).
   PubMed Web of Science ®Google Scholar
• The UK Collaborative HIV cohort (CHIC) Steering Committee. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS24, 723–727 (2010).
   PubMed Web of Science ®Google Scholar
• Wolbers M, Bucher HC, Furrer H et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med.9(6), 397–405 (2008).
   PubMed Web of Science ®Google Scholar
• Kivela PS, Krol A, Salminen MO, Ristola MA. Determinants of late HIV diagnosis among different transmission groups in Finland from 1985 to 2005. HIV Med.11(6), 360–367 (2010).
   PubMed Web of Science ®Google Scholar
• Ulett KB, Willig JH, Lin H-Y et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDs23(1), 41–49 (2009).
   PubMed Web of Science ®Google Scholar
• Althoff KN, Gange SJ, Klein MB et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin. Infect. Dis.50(11), 1512–1520 (2010).
   PubMed Web of Science ®Google Scholar
• Krentz HB, Gill J. Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 µl. AIDS24(17), 2750–2753 (2010).
   PubMedGoogle Scholar
• Girardi E, Aloisi MS, Arici C et al. Delayed presentation and late testing for HIV: demographic and behavioural risk factors in a multicenter study in Italy. J. Acquir. Immune Defic. Syndr.36(4), 951–959 (2004).
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Skanderson M, Gordon KS, Concato J, Justice AC. Delayed presentation for human immunodeficiency virus (HIV) care among veterans. A problem of access or screening? Med. Care45(11), 1105–1109 (2007).
   PubMed Web of Science ®Google Scholar
• Kigozi IM, Dobkin LM, Martin JN et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J. Acquir. Immune Defic. Syndr.52(2), 280–289 (2009).
   PubMed Web of Science ®Google Scholar
• Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin. Infect. Dis.52(Suppl. 2), S238–S246 (2011).
   PubMed Web of Science ®Google Scholar
• Marcellin F, Abe C, Loubiere S et al. Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS23(8), 1015–1019 (2009).
   PubMedGoogle Scholar
• Torian LV, Wiewel EW, Liu K-L, Sackoff JE, Frieden TR. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch. Int. Med.168(11), 1181–1187 (2008).
   PubMed Web of Science ®Google Scholar
• Antinori A, Johnson M, Moreno S, Yazdanpanah Y, Rockstroh JK. Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antiviral Ther.15(Suppl. 1), 31–35 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir. Ther.15(Suppl. 1), 3–8 (2010).
   PubMed Web of Science ®Google Scholar
• Antinori A, Coenen T, Costagliola D et al. Late presentation of HIV infection: a consensus definition. HIV Med.12, 61–64 (2011).
   PubMed Web of Science ®Google Scholar
• Ndiaye B, Salleron J, Vincent A et al. Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997–2007. BMC Infect. Dis.11, 11 (2011).
   PubMed Web of Science ®Google Scholar
• Bamford LP, Ehrenhranz PD, Eberhart MG, Shpaner M, Brady KA. Factors associated with delayed entry into primary HIV medical care after HIV diagnosis. AIDS24(6), 928–920 (2010).
   PubMed Web of Science ®Google Scholar
• Althoff KN, Gebo KA, Gange SJ et al. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res. Ther.7, 45 (2010).
   PubMedGoogle Scholar
• Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin. Infect. Dis.45, 1369–1374 (2007).
   PubMed Web of Science ®Google Scholar
• Smit C, Hallett TB, Lange J, Garnett G, de Wolf F. Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS ONE3, e1949 (2008).
   Google Scholar
• Chadborn TR, Baster K, Delpech VC et al. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993–2002). AIDS19, 513–520 (2005).
   PubMed Web of Science ®Google Scholar
• Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans SG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). AIDS20, 2371–2379 (2006).
   PubMed Web of Science ®Google Scholar
• Lucas SB, Curtis H, Johnson MA. National review of deaths among HIV-infected adults. Clin. Med.8(3), 250–252 (2008).
   PubMed Web of Science ®Google Scholar
• Torti C, Lapadula G, Maggiolo F et al. Predictors of AIDS-defining events among advanced naive patients after HAART. HIV Clin. Trials8(3), 112–120 (2007).
   PubMed Web of Science ®Google Scholar
• Berry SA, Manabe YC, Moore RD, Gebo KA. Hospitalization risk following initiation of highly active antiretroviral therapy. HIV Med.11, 289–298 (2010).
   PubMedGoogle Scholar
• Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4<200 cells/µl) with HIV infection. HIV Med.5, 93–98 (2004).
   PubMed Web of Science ®Google Scholar
• Gebo KA, Fleishman JA, Conviser R et al. Contemporary costs of HIV healthcare in the HAART era. AIDS24(17), 2705–2715 (2010).
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet360, 119–129 (2002).
   PubMed Web of Science ®Google Scholar
• Waters L, Fisher M, Anderson J et al. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. HIV Med.12(5), 289–298 (2011).
   PubMedGoogle Scholar
• Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med.342, 921–929 (2000).
   PubMed Web of Science ®Google Scholar
• Marks G, Crepaz N, Janssen RS et al. Estimating sexual transmission of HIV from persons aware and unaware they are infected with the virus in the USA. AIDS26, 1447–1450 (2006).
   Google Scholar
• Moreno S, Mocroft A, d’Arminio Monforte A. Medical and societal consequences of late presentation. Antivir.Ther.15(Suppl. 1), 9–15 (2010).
   PubMed Web of Science ®Google Scholar
• Mocroft A, Reiss P, Gasiorowski J et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J. Acquir. Immune Defic. Syndr.55(2), 262–270 (2010).
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Gatell J, Landman R, Antinori A. Management of late-presenting patients with HIV infection. Antivir. Ther.15(Suppl. 1), 25–30 (2010).
   PubMed Web of Science ®Google Scholar
• Zolopa A, Andersen J, Powderly W et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE4, e5575 (2009).
   PubMed Web of Science ®Google Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin. Infect. Dis.50(11), 1532–1538 (2010).
   PubMed Web of Science ®Google Scholar
• Grant PM, Aberg JA, Zolopa AR. Concerns regarding a randomized study of the timing of antiretroviral therapy in Zimbabweans with AIDS and acute cryptococcal meningitis. Clin. Infect. Dis.51(8), 984–985 (2010).
   PubMedGoogle Scholar
• Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med.362(8), 697–706 (2010).
   PubMed Web of Science ®Google Scholar
• Karim SA, Naidoo K, Padayatchi N et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 27 February–2 March 2011.
   Google Scholar
• Blanc FX, Sok T, Laureillard D et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18–23 July 2010.
   Google Scholar
• Havlir D, Ive P, Kendall M et al. International randomized trial of immediate vs early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE Study. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011.
   Google Scholar
• Torok ME, Yen NTB, Chau TT et al. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. Presented at: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Hansel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of protease inhibitor-naive HIV-infected patients. J. Acquir. Immune Defic. Syndr.26(2), 191–193 (2001).
   PubMedGoogle Scholar
• Uy J, Yang R, Thiry A et al. Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated with atazanavir/r and lopinavir/r in the CASTLE study. J. Intl AIDS Soc.11(Suppl. 1), P8 (2008).
   PubMedGoogle Scholar
• Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet374(9692), 796–806 (2009).
   PubMed Web of Science ®Google Scholar
• Lewden C, Chene G, Morlat P et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr.46(1), 72–77 (2007).
   PubMed Web of Science ®Google Scholar
• Tan R, Westfall AO, Willig JH et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr.47(5), 553–558 (2008).
   PubMed Web of Science ®Google Scholar
• Zoufaly A, an der Heiden M, Kollan C et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J. Infect. Dis.203(3), 364–371 (2011).
   PubMed Web of Science ®Google Scholar
• Kelley CF, Kitchen CM, Hunt PW et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis.48(6), 787–794 (2009).
   PubMed Web of Science ®Google Scholar
• Negredo E, Massanella M, Puig J et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin. Infect. Dis.50(9), 1300–1308 (2010).
   PubMed Web of Science ®Google Scholar
• Kaufmann GR, Furrer H, Ledergerber B et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/µl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis.41(3), 361–372 (2005).
   PubMed Web of Science ®Google Scholar
• Abrams D, Lévy Y, Losso MH et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med.361(16), 1548–1559 (2009).
   PubMed Web of Science ®Google Scholar
• Tincati C, Cesari M, Meroni L et al. Clinical effect of interleukin-2 (IL-2) immuno-adjuvant treatment in HIV+ advanced naive patients. J. Intl AIDS Soc.11(Suppl. 1), P1 (2008).
   PubMedGoogle Scholar
• Levy Y, Lacabaratz C, Weiss L et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest.119(4), 997–1007 (2009).
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Fath MJ, Demasi R et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS20(16), 2051–2064 (2006).
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann. Intern. Med.154(7), 445–456 (2011).
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC et al. Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy. N. Engl. J. Med.361(23), 2230–2240 (2009).
   PubMed Web of Science ®Google Scholar
• Lanoy E, Guiguet M, Bentata M et al. Survival after neuroAIDS: association with antiretroviral CNS penetration-effectiveness score. Neurology76(7), 644–651 (2011).
   PubMed Web of Science ®Google Scholar
• Ellis R, Badiee J, Letendre S et al. Nadir CD4 is a predictor of HIV neurocognitive impairment (NCI) in the era of combination antiretroviral therapy (cART): results from the CHARTER study. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18–23 July 2010.
   Google Scholar
• Ho J, Deeks S, Hecht F et al. Earlier initiation of ART in HIV-infected individuals is associated with reduced arterial stiffness. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16–19 February 2010.
   Google Scholar
• Crum-Cianflone N, Ganesan A, Teneza-Mora N et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDs24(6), 353–360 (2010).
   PubMed Web of Science ®Google Scholar
• Young B, Dao CN, Buchacz K et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin. Infect. Dis.52(8), 1061–1068 (2011).
   PubMed Web of Science ®Google Scholar
• Dauby N, De Wit S, Delforge M et al. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J. Intl AIDS Soc.14(1), 16 (2011).
   PubMedGoogle Scholar
• Gonzalez JS, Penedo FJ, Llabre MM et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann. Behav. Med.34(1), 46–55 (2007).
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Benson C, Holmes KH et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Rec. Rep.58(RR-4), 1–207 (2009).
   PubMedGoogle Scholar
• Mocroft A, Reiss P, Kirk O et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/µl? Clin. Infect. Dis.51(5), 611–619 (2010).
   PubMed Web of Science ®Google Scholar
• D’Egidio GE, Kravcik S, Cooper CL et al. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/µl when viral replication is suppressed. AIDS21(13), 1711–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Geretti AM, Brook G, Cameron C et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med.9(10), 795–848 (2008).
   PubMed Web of Science ®Google Scholar
• Waters LJ, Fisher M, Anderson J, Wood C, Sabin C. Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART? J. Int. AIDS Soc.11(Suppl. 1), O44 (2008).
   Google Scholar
• Yazdanpanah Y, Lange J, Gerstoft J, Cairns G. Earlier testing for HIV – how do we prevent late presentation? Antivir. Ther.15(Suppl. 1), 17–24 (2010).
   PubMed Web of Science ®Google Scholar
• Leon N, Naidoo P, Mathews C, Lewin S, Lombard C. The impact of provider-initiated (opt-out) HIV testing and counseling of patients with sexually transmitted infection in Cape Town, South Africa: a controlled trial. Implement Sci.5, 8 (2010).
   PubMed Web of Science ®Google Scholar
• Apoola A, Brunt L. A randomised controlled study of mouth swab testing versus same day blood tests for HIV infection in young people attending a community drug service. Drug Alcohol Rev.30(1), 101–103 (2011).
   PubMedGoogle Scholar
• Department of Health. Screening for Infectious Diseases in Pregnancy: Standards to Support the UK Antenatal Screening Programme (2003).
   Google Scholar
• Mounier-Jack S, Nielsen S, Coker RJ. HIV testing strategies across European countries. HIV Med.9(Suppl. 2), 13–19 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher M. Roll-out of expanded HIV testing: how are we doing? Presented at: 17th Annual British HIV Association Conference. Bournemouth, UK, 6–8 April 2011.
   Google Scholar
• Ellis S. HIV testing and diagnosis. Presented at: 17th Annual British HIV Association Conference. Bournemouth, UK, 6–8 April 2011.
   Google Scholar
• McDaid LM, Hart GJ. Increased HIV testing and reduced undiagnosed infection among gay men in Scotland, 2005–2008: support for the opt-out testing policy? Sex. Transm. Infect.87(3), 221–224 (2011).
   PubMed Web of Science ®Google Scholar
• Adams ST, Leveson SH. Should blood-borne virus testing be part of operative consent? When the doctor becomes the patient. J. Med. Ethics37(8), 476–478 (2011).
   PubMedGoogle Scholar
• Kall M, Delpech V, Thornton A, Nardone A. Where do we diagnose HIV? Monitoring new diagnoses made in non-traditional settings. Presented at: 17th Annual British HIV Association Conference. Bournemouth, UK, 6–8 April 2011.
   Google Scholar
• Health Protection Agency. HIV in the United Kingdom: 2010 Report. Health Protection Report4(47), (2010).
   Google Scholar
• Apea V, Khan P, de Masi A et al. Newly diagnosed HIV infection in an inner London genito-urinary medicine (GUM) clinic. HIV Med.10(Suppl. 1), (2009) (Abstract P13).
   Google Scholar